Last reviewed · How we verify

Bypassing Agents — Competitive Intelligence Brief

Bypassing Agents (Bypassing Agents) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bypassing coagulation agent. Area: Hematology.

phase 3 Bypassing coagulation agent Factor X / Tissue factor pathway Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Bypassing Agents (Bypassing Agents) — Hoffmann-La Roche. Bypassing agents are coagulation factors that activate the coagulation cascade downstream of factors VIII and IX to restore thrombin generation in patients with inhibitors to these factors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bypassing Agents TARGET Bypassing Agents Hoffmann-La Roche phase 3 Bypassing coagulation agent Factor X / Tissue factor pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bypassing coagulation agent class)

  1. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bypassing Agents — Competitive Intelligence Brief. https://druglandscape.com/ci/bypassing-agents. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: